
- /
- Supported exchanges
- / US
- / ABCL.NASDAQ
Abcellera Biologics Inc (ABCL NASDAQ) stock market data APIs
Abcellera Biologics Inc Financial Data Overview
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Abcellera Biologics Inc data using free add-ons & libraries
Get Abcellera Biologics Inc Fundamental Data
Abcellera Biologics Inc Fundamental data includes:
- Net Revenue: 23 114 K
- EBITDA: -231 196 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abcellera Biologics Inc News

Abcellera Biologics stock hits 52-week high at 4.09 USD
Abcellera Biologics Inc. (ABCL) stock reached a 52-week high, trading at 4.09 USD. This milestone comes as the company experiences a significant 1-year change, with its stock appreciating by 46%. Acco...


Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 13 Stocks Under $5 With High Upside Potential. On May 16, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biolog...

Leerink Partners assumes coverage on AbCellera stock with Outperform rating
Investing.com - Leerink Partners has assumed coverage on AbCellera Biologics (NASDAQ:ABCL) with an Outperform rating and a $5.00 price target, according to a research note released Monday. The stock h...

Village Farms International And 2 Other Promising Penny Stocks For Your Watchlist
The market has climbed by 2.1% over the past week and 14% in the last year, with earnings forecasted to grow annually by 15%. Amid these conditions, identifying stocks that combine financial health wi...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.